DA-1726

NeuroBo Pharmaceuticals' DA-1726 Demonstrated Superiority in Weight Loss, Retention of Lean Body Mass, and Lipid-Lowering Effects Compared to Survodutide, in Pre-Clinical Models
BioSpace
Mon, 06/24/24 - 11:24 am
NeuroBo Pharmaceuticals
DA-1726
ADA
weight loss
FDA approves NeuroBo’s DA-1726 application to begin Phase I trial
Clinical Trials Arena
Fri, 02/2/24 - 11:55 am
NeuroBo Pharmaceuticals
DA-1726
FDA
clinical trials
obesity
NeuroBo signs license deal with Dong-A ST to develop two drug candidates
Pharmaceutical Business Review
Fri, 09/16/22 - 10:16 am
NeuroBio
Dong-A ST
drug development
DA-1241
DA-1726
cardiometabolic diseases